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 Abstract: The search for novel nucleosides has been a major research focus in medicinal chemistry 
for several decades, particularly given their proven track record in the treatment of viral infections and 
cancer. As bioisosteres of natural nucleosides, thionucleosides are especially attractive targets as they 
often display improved biological activity. Furthermore, replacement of oxygen with sulfur may 
sometimes be accompanied by interesting changes in pharmacological effect. This update covers 
recent advances in the preparation of novel thionucleosides, grouped by synthetic strategy. The 
biological properties of the target thionucleosides are also summarised, in addition to any reported 
structure activity relationships.  
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1. INTRODUCTION 
Nucleosides have been of clinical importance for decades in the treatment of cancer and 
viral infections, with idoxuridine being the first drug of this class to receive approval for 
use in humans in the early 1960s.
1
 The development of novel nucleosides has been the 
focus of intense research activity over the years, and has led to the emergence of several 
new sub-classes with improved pharmacological profiles, including nucleotides and 
acyclic analogues.2-7 Likewise, thionucleosides have been attractive targets to medicinal 
chemists.
8
 As bioisosteres of cell-native 4´-oxonucleosides, 4´-thionucleosides contain a 
more stable glycosyl bond between the sugar and nucleoside base, conferring increased 
metabolic stability to most cellular and viral enzymes.
9-13
 Additionally, replacement of 
oxygen with sulfur is sometimes accompanied by unexpected changes in biological 
activity.14-16 
  




 in the early 2000s, this update covers 
recent advances in the design and synthesis of novel thionucleosides and also examines 
their reported biological effects. This review is subdivided according to the synthetic 
strategy employed to synthesise the target thionucleosides, namely: 1. Vorbrüggen 
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glycosylation; 2. Pummerer glycosylation; 3. Electrophilic glycosylation; 4. Late-stage 






2. VORBRÜGGEN GLYCOSYLATIONS  
 
Also known as the Silyl-Hilbert-Johnson reaction, the Vorbrüggen glycosylation is 
probably the most commonly used method to prepare nucleosides.
18-20
 This 
transformation is typically conducted using a Lewis acid catalyst, such as 






Miller and colleagues exploited commercially available L-ascorbate-derived epoxide 12 
to access novel 2´-deoxy-4´-thionucleosides (Scheme 3).
21
 Exclusive opening of epoxide 
12 at the less hindered carbon by lithiated dithianes afforded hydroxydithioacetals 16-
18.22, 23 Manipulation of the protecting groups in 16-18, followed by mesylation of the 
free hydroxyl, furnished 19-21. Cyclisation of mesylates 19-21, where R was a phenyl 
or ethyl group, was not achieved despite recourse to a range of conditions. A mixture of 
E- and Z-vinyl sulfides 22-24 were instead formed as a result of a 1,4-thiolate shift. 
However, the tert-butyl analogue did cyclise in the presence of DBU to form a mixture 
of α- and β-thiosugars 25 in 50-60% yield. The authors postulate that the kinetics of 
ring-closure can compete with the 1,4-thiolate shift as DBU facilitates de-tert-butylation 
via loss of isobutylene. Glycosylation of 25 was achieved using silylated thymine 
analogue 26 in the presence of N-bromosuccinimide (NBS) in acetonitrile. Following 
standard deprotection procedures, 4´-thionucleoside 27 was isolated in 53% yield as a 
2:3 mixture of β- and α-isomers. The β-isomer was previously reported by Rahim et al. 







In their studies on the anti-cancer activity of novel 4´-thio-5-azacytosine analogues, 
Secrist et al. exploited a Vorbrüggen-type glycosylation of 5-azacytosine 29 and glycal 
donor 2825-27 in their key step (Scheme 4). The resulting 2:1 anomeric mixture of 
(S,S,R)-30 and (R,S,R)-30 was separated by column chromatography. Following 
independent deprotection of the 3´- and 5´-hydroxyl groups of both the α- and β-
anomers, diols (S,S,R)-31 and (R,S,R)-31 were isolated. However, (S,S,R)-31 and 
(R,S,R)-31 were found to be unstable in solution. By contrast, reduction of the 
azacytosine 5,6-double bond with sodium borohydride and subsequent methoxide-






This chemistry was repeated on the L-enantiomers to produce stereoisomers (S,S,R)-34, 
(R,S,R)-34, (S,S,R)-35 and (R,S,R)-35 (Figure 1). When assayed for their antitumour 
activity, only (R,S,R)-33 displayed any cytotoxic effect on the cell lines tested (Table 1). 
(R,S,R)-33 progressed to in vivo studies in female nude mice which were implanted 
subcutaneously with NCI-H23 non-small cell lung tumour. When 4.5 mg/kg of (R,S,R)-
33 was injected as a single dose on days 15-23, the lifespan of the infected mice 
increased by 8 days in comparison to the control models. Interestingly, when (R,S,R)-33  
was freshly prepared it increased mouse lifespan by an average of 10.9 days, suggesting 
















Figure 1. Novel azacytosine-derived thionucleosides 
Table 1: Anti-cancer activity of thionucleoside (R,S,R)-33 
















(R,S,R)-33 0.01 13.0 7.0 3.1 5.3 1.7 
 
Several research groups have observed that 5-substituted pyrimidines display potent 
anti-herpes virus activity.28, 29  In light of these findings, Simons et al. designed a library 
of novel 5-substituted-6-aza-pyrimidine-4´-thionucleosides paying particular attention to 
the L-thionucleosides (Scheme 5).30 5-Ethyl- (41) and 5-propyl-6-azapyrimidines (42) 
were prepared from the corresponding 2-keto-carboxylic acids 36 and 37 respectively 
via semicarbazones 39 and 40. Pyrimidines 41 and 42, along with commercially 
available 5-methyl-6-azapyrimidine (43), were coupled to 4´-thiosugar 44, which was 
itself synthesised using Dyson’s methodology.
31
 A modified Vorbrüggen reaction was 
next employed, whereby an iodine-based reagent such as iodine monochloride or N-
iodosuccinimide (NIS), was used in place of a Lewis acid.
32
 Approximately 1:1 ratios of 
the α- and β-nucleoside products 45-47 were recovered. Following debenzylation with 
boron trichloride, α- and β-anomers 48-50 were separated by column chromatography, 
albeit in low yields of the desired β-products. 4´-Thioribose 51 was prepared in a similar 





Scheme 5  
 
 
Straightforward manipulation of the 1,6-azathymine (R,S,R)-50 nucleobase provided 
access to 4-thione 54 and 5-methylcytidine 55 derivatives in good yields (Scheme 6). 
Acetylation of the 5´- and 3´-hydroxyls furnished 52 which was converted to thione 53 
after treatment with Lawesson’s reagent in 48% overall yield. Deacetylation of 53 in 
ammonia solution in methanol at 0 °C produced diol 54, while amination of 53 to form 





Scheme 6  
The five 2-aza-4´-thionucleosides (R,S,R)-48, (R,S,R)-49, (R,S,R)-50, 54 and 55 were 
tested for biological activity against a range of viruses. None were found to have any 
activity below toxic concentrations against reovirus-1, coxsackie virus B4, sindbis virus, 
parainfluenza-3 virus, Punta Toro virus, vesicular stomatitis virus, respiratory syncytial 
virus or cytomegalovirus. Thionucleoside (R,S,R)-50 was found to have activity 
comparable to that of acyclovir against various strains of varicella-zoster virus. (R,S,R)-
50 also displayed inhibitory activity towards vaccinia virus andherpes simplex virus 
strains HSV-1 and HSV-2.  
 
In later work, the synthesis and antiviral activity of two related 6-azathymidine-4´-
thionucleosides was described.
33
 Silylation of the 5´-hydroxyl of (R,S,R)-50 afforded 
alcohol 56 (Scheme 7). The 3´-hydroxyl was then removed over two steps via Barton-
McCombie radical deoxygenation to form thiolane 60 in 64% yield.34 Desilylation of 60 





Scheme 7  
Following biological testing, thiolane 61 exhibited moderate activity towards vaccinia 
virus, HSV-1 and HSV-2. Most interestingly, its activity was retained against the 
thymidine kinase-deficient HSV-1 TK
-
 viral strain, suggesting its activity is not 
dependent on viral thymidine kinase-catalysed phosphorylation. 
 
In their search for compounds with anti-HIV activity, Chu et al. synthesised a range of 
2´,3´-dideoxy-2´,3´-didehydro-2´-fluoro-4´-thionucleosides (Scheme 8).
35
 A modified 
Horner-Emmons reaction was performed on aldehyde 62 using fluorinated phosphonate 
63 to produce 64 in a 9:1 ratio of E- and Z-isomers. Hydrolysis of acetal 64 in 
concentrated hydrochloric acid was accompanied by in situ cyclisation. Subsequent 
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silylation of the 5´-hydroxyl group afforded 65. Reduction of alkene 65 was followed by 
ring-opening, methylation and Garegg-Samuelsson-type iodination to afford iodo-ester 
67. Nucleophilic substitution with thioacetate allowed for the introduction of sulfur. 
Reduction of 68 with DIBAL-H promoted cyclisation to form a β-thiolactol which was 
subsequently oxidised to β-thiolactone 69 in a Moffatt-type reaction. The minor isomer 
of 69 was also formed in 6% yield and was found to be separable by column 
chromatography. Introduction of a 2´-phenylselenyl group was used as a means of 
directing β-selectivity during the glycosylation. The silyl enol ether of 69 was formed in 
situ, and subsequently reacted with phenylselenyl bromide to furnish 70. Reduction of 
β-thiolactone 70 was followed by in situ acetylation to form glycosyl-donor 71. 
Condensation of acetate 71 with various nucleobases was conducted under Vorbrüggen 
conditions to exclusively furnish β-anomers 72-79 (Table 2), due to the bulky α-
phenylselenyl group directing stereochemistry. Selenide oxidation with mCPBA was 
followed by spontaneous syn-elimination of the resulting selenoxide. The 5´-silyl 






Table 2: Yields of selenides 72-79 and thionucleosides 80-87 
Entry Selenide Base Yield Thionucleoside Yield 
1 72 Cytosine 80% 80 88% 
2 73 5-Fluorocytosine 73% 81 88% 
3 74 Uracil 68% 82 92% 
4 75 Thymine 76% 83 91% 
5 76 Adenine 86% 84 57% 
12 
 
6 77 Hypoxanthine 86% 85 81% 
7 78 Guanine 86% 86 61% 
8 79 2-Fluoroadenine 28% 87 70% 
 
The authors also conducted molecular modelling studies to elucidate possible structure 
activity relationships, and found that although the 4´-sulfur is well tolerated in place of 
oxygen, steric hindrance is increased due to the unnatural L-configuration of the sugar. 
The phenomenon can be observed where the β-branched chain of valine in M184V-
mutant HIV-strains confers cross-resistance to the NRTI lamivudine. From the 
biological data presented in Table 3, it is apparent that cytosine 80, 5-F-cytosine 81 and 
adenine 84 display anti-HIV-1 activity in peripheral blood mononuclear (PBM) cells 
comparable to the NRTI zidovudine (AZT). These compounds were also found to be 
non-cytotoxic.   
 
Table 3: Anti-HIV activity of thionucleosides 80-87 compared to AZT 
Entry Thionucleoside Anti-HIV-1 activity 
(EC50, µM) 
Cytotoxicity (IC50, µM) 
  PBM PBM CEM Vero 
1 80 0.12 >100 >100 >100 
2 81 0.15 >100 >100 >100 
3 82 >100 >100 >100 >100 
4 83 >100 >100 >100 >100 
5 84 1.7 >100 >100 >100 
6 85 15.5 >100 >100 >100 
7 86 43.5 >100 41.5 66.4 
8 87 11.5 13.0 10.4 66.1 
13 
 
9 AZT 0.004 >100 29.0 14.3 
 
Several novel 4´-thio-L-ribonucleosides have been synthesised by Pejanovic and co-
workers, and subsequently evaluated for their anti-tumour activity.
20
 α-D-
Lyxopyranoside (88) (Scheme 9) was initially prepared using the route outlined by 
Reist.
8, 36
  Following selective alcohol protection of 88, acetal 89 was converted to 
thioacetate 90 via its triflic ester, using potassium thioacetate in a nucleophilic 
displacement reaction. Hydrolysis of the acetal protecting group afforded a mixture of 
products that were subjected to acetylation to form thiophene derivative 91, exclusively 
as the β-anomer. Addition of a persilylated base to sugar 91 and trimethylsilyl triflate 
afforded the corresponding acetoxy-protected nucleosides 92-95 in yields of 48-79% 
(Table 4). Alcohol deprotection was achieved by stirring in sodium methoxide and 





Scheme 9  
Table 4: Yields for the conversion of 91 to 92-95 and subsequent deprotection to 96-99 





1 5-Fluorouracil 92 79% 96 49% 
2 5-Fluorocytosine 93 59% 97 67% 
3 Thymine 94 54% 98 46% 
4 6-Thioguanine 95 48% 99 90% 
 
In total, four thionucleosides were prepared and tested for in vitro cytotoxicity to C6 rat 
glioma, HTB14 human glioma, HeLa human cervical carcinoma, NB4 leukemia, T47D 
breast cancer and normal human dermal fibroblast (NHDF) cell lines (Table 5). 
Analgoues 97 and 99 are believed to be the first nucleoside analogues with growth 
15 
 
stimulatory activity (GSA) towards NB4 and T47D cells. None of the candidates 
exhibited growth inhibitory effects on the NHDF cell line at any of the tested 
concentrations, consistent with findings that L-nucleoside analogues are ordinarily less 
toxic to normal cells due to native cellular enzymes not recognising them. 
 
Table 5: In vitro cytotoxicity of thionucleosides 96-99 
 
Entry Thionucleoside IC50 µM 
  C6 HTB14 HeLa NB4 T47D NHDF 
1 96 >100 41.5 >100 >100 >100 >100 
2 97 >100 83.3 95.9 GSA GSA >100 
3 98 >100 67.8 100 >100 >100 >100 
4 99 >100 62.1 >100 >100 GSA >100 
 
A library of 1´-α-substituted-4´-thionucleosides (106-110) was created by Jeong and 
colleagues and assessed for their ability to bind with the adenosine A3 receptor (Scheme 
10).37 Diol 101 was prepared over four steps from D-gulonic-γ-lactone (100) using a 
previously published methodology.
38
 Treatment of diol 101 with one equivalent of lead 
tetraacetate at 0 °C produced the corresponding aldehyde. By contrast, repeating the 
16 
 
reaction with excess reagent at room temperature instead afforded acetate 102, most 
likely via a sulfonium ion intermediate. Condensation of 102 with persilylated 2,6-
dichloropurine, employing trimethylsilyl triflate as a Lewis acid catalyst, produced 103 
as a single stereoisomer. Transformation of the isopropylidene group to 
ditetrahydropyranoether 104 was carried out to prevent deglycosylation during the final 
deprotection step. Deprotonation with lithium hexamethyldisilazide, followed by 
addition of methyl chloroformate, furnished 105 as a single stereoisomer. The authors 
attribute this high stereoselectivity to the formation of a stable 5-membered ring via 1´-
lithium co-ordination to N
3
, blocking β-attack by the electrophile. Finally, a range of 
1´,2´-substituted-4´-thionucleosides 106-110 were synthesised via selective N6-
amination of 105, followed by conversion of the methyl ester group to the methyl amide 
moiety and deprotection of the 2´- and 3´-alcohol groups by para-toluenesulfonic acid. 





The same group prepared a library of apiothionucleosides lacking a 5´-functionality as 
potential Human A3 AR ligands.
39
 Diol 101,  synthesised in good yield over five steps 
from D-mannose (111), was converted to glycosyl donor 102 with an excess of lead 
tetraacetate (Scheme 11). Acetal 102 underwent Vorbrüggen-type glycosylation with 
persilylated 2,6-dichloropurine in the presence of trimethylsilyltriflate. The acetal group 
of nucleoside 103 was removed to form diol 112 in excellent yield. Synthesis of target 
18 
 
nucleosides 113-122 was achieved by treatment of 112 with various substituted 
alkylamines and arylalkylamines to afford the final products in good yields. 
 
Scheme 11  
The binding affinities of compounds 113-122 were measured and compared to that of 
known agonist Cl-IB-MECA (123) (Table 6). While most of the compounds exhibited 
high binding affinity at the human A3 AR, 3-chlorobenzyl analogue 114 displayed the 
highest, and most selective, binding affinity (Entry 2). The results show that 3-
substitution of the aromatic ring is preferable to either 2- or 4-substitution.  


















  Affinity, Ki, nM ± SEM (or % inhibition) 
Entry Compound hA1 hA2A hA3 
1 113 20% 48% 7.4 ± 1.3 
2 114 38% 18% 1.66 ± 0.90 
3 115 34% 18% 8.99 ± 5.17 
4 116 2490 ± 940 341 ± 75 4.16 ± 0.50 
5 117 13% 1600 ± 135 25.8 ± 6.3 
6 118 24% 4020 ± 1750 12.7 ± 3.7 
7 119 9% 18% 19.9 ± 7.1 
8 120 22% -8% 24.8 ± 8.1 
9 121 13% 0% 42% 
10 122 55.4 ± 1.8 45.0 ± 1.4 3.69 ± 0.25 
15 123(Cl-IB-MECA) 222 ± 22 5360 ± 2470 1.4 ± 0.3 
 
In a continuation of this work, the authors synthesised and tested HSP90 (heat shock 
protein) inhibitors for their potential application in cancer treatment.40 Initial protection 
of diol 101 was followed by cleavage of the acetal to form 124 (Scheme 12). Silylation 
of diol 124 and subsequent debenzoylation furnished 125 in 66% yield. Treatment of 
diol 125 with lead tetraacetate resulted in the formation of acetate 126. Glycal donor 126 
20 
 
underwent Vorbrüggen-type glycosylation with in situ persilylated purine 127 in the 
presence of trimethylsilyltriflate. Amination at C-6 was achieved with ammonia in tert-
butanol, and final desilylation with TBAF afforded 129, an 8-iodo-adenine derivative. 




All twenty-three compounds were tested for HSP90 inhibitory activity, but only 129 was 
found to be active, albeit weakly so (Table 7, Entry 1). The library was also tested for 
anticancer activity on five different cell lines: A549 (human lung cancer), Caki-1 
(human renal cancer), HCT116 (human colon cancer), MDA-MB-231 (human breast 
cancer) and SNU638 (human stomach cancer). Interestingly, the most potent anticancer 
activity across all cell lines was again seen in 129, which lacks a 5´-hydroxyl group 
essential for cellular phosphorylation and therefore cannot be directly incorporated into 
a DNA chain. This would suggest that an alternate mechanism of action is at play. The 
results of the biological evaluation confirm that the 8-iodo-4´-thioadenosine analogues, 




Table 7: Anticancer activity of thionucleosides 129-151 against several tumour cell lines 
 
 
     IC50 (µM) 






1 129 I H H 7.85 6.14 4.56 6.3 3.99 
2 130 Furanyl CH2OH H >100 >100 >100 >100 >100 
3 131 Thiofuranyl CH2OH H >100 66.3 >100 >100 >100 
4 132 Piperidinyl CH2OH H >100 >100 >100 >100 >100 
5 133 Phenyl CH2OH H >100 >100 >100 >100 >100 
6 134 CH3(CH2)2 NH CH2OH H  >100 >100 99.45 90.72 99.68 
7 135 N3 CH2OH H >100 >100 >100 >100 >100 
8 136 NHMe CH2OH H >100 >100 >100 >100 >100 
9 137 I CH2OH H 42.32 50.53 22.24 8.18 15.94 
10 138 I CH2OB
z 
H 38.54 19.06 15.89 21.17 34.51 
11 139 Furanyl H H 99.64 55.2 99.76 67.39 99.67 
12 140 Furanyl H Me >100 >100 >100 >100 >100 
13 141 Thiofuranyl H H >100 >100 >100 >100 >100 
22 
 
14 142 Thiofuranyl H Me >100 >100 >100 >100 >100 
15 143 N3 H H >100 >100 >100 >100 >100 
16 144 NHMe H H >100 >100 >100 >100 >100 
17 145 CH3(CH2)2NH H H >100 >100 >100 >100 >100 
18 146 BnNH H H >100 >100 >100 >100 >100 
19 147 Piperonyl- amino H H >100 >100 >100 >100 >100 
20 148 Piperidinyl H H >100 >100 >100 >100 >100 
21 149 Furanyl H Cl 11.1 70.85 69.79 51.13 44.47 
22 150 Thiofuranyl H Cl 9.35 49.92 48.9 62.39 27.78 
23 151 N3 H Cl >100 >100 >100 >100  >100 
 
A series of novel, fluorinated thiopyranonucleosides have been prepared by Komiotis et 
al. (Scheme 13).
41
 Oxidative cleavage of diol 152 was followed by reduction, tosylation 
and treatment with thioacetate to furnish 153 in 74% yield overall.42 Cleavage of the 
acetal in 153, followed by hydrolysis of the thioacetate, produced a thiol which 
underwent in situ cyclisation to the 6-membered thiopyranose ring 155. Using 
Vorbrüggen glycosylation conditions, addition of presilylated thymine to acetylated 155 





Scheme 13  
Synthesis of 5-thioglucopyranose derivative 161 was achieved in a similar manner from 
152 (Scheme 14). Selective benzoylation of the primary alcohol was followed by 
mesylation of the secondary alcohol to produce 157. Addition of sodium methoxide 
promoted epoxide formation affording 158. Epoxide 158 was converted to a thiirane 
intermediate, which was then subjected to acetolysis and subsequent acetal hydrolysis to 
furnish furanose 159 in 46% overall yield. The final steps of the synthesis are the same 






Scheme 14  
In later work, Komiotis et al. described the synthesis of 2´-keto- and 4´-keto-
xylopyranothymidine analogues (Scheme 15).
43
 Deacetylation of 3´-deoxy-3´-fluoro-5´-
S-acetyl-5´-thio-D-xylofuranose (154) and concomitant rearrangement to thiopyranose 
155, was followed by acetalisation at the 1´- and 2´-positions to provide 163. Alcohol 
163 was converted to its acetate, then the acetal protecting group was removed and 
replaced with benzoyl esters as per glycosyl donor 164. Subsequent Vorbrüggen 
condensation was conducted on persilylated thymine and 164 in the presence of tin 
tetrachloride to form 165 exclusively as the β-anomer. Selective 4´-deacetylation 




Scheme 15  
Synthesis of the 2´-keto derivative 171 was achieved in a mostly similar manner from 
key intermediate 163 (Scheme 16). 163 was initially benzoylated at the 4´-position, and 
the 2´- and 3´-hydroxyl groups were acetylated following acetal deprotection. Acetate 
168 then underwent Vorbrüggen-type glycosylation, followed by 2´-deacetylation and 
subsequent oxidation to form 2´-keto analogue 171. The authors did not reveal results 





Scheme 16  
The synthesis of 2´-deoxy-2´-fluoro-4´-thioribonucleosides and 2´-modified-4´-
thioribonucleosides was described by Matsuda et al. in separate papers in 2008 and 2009 
respectively.44, 45 They employed a previously optimised methodology based on the 
Pummerer reaction (Scheme 17).
46
 Acidic hydrolysis of ribose 172 was followed by 
reduction of the resultant lactol by sodium borohydride. The resulting diol was 
selectively protected at the primary position, leading to formation of silane 173 in 84% 
yield. A subsequent Mitsunobu reaction with p-nitrobenzoic acid afforded L-lyxose 
derivative 174. Deprotection of the p-nitrobenzoyl group was followed by removal of 
the silyl group to form diol 175, which was bis-mesylated and then treated with sodium 
sulfide to furnish thioribose analogue 176 in 53% overall yield. Protection of the 3´- and 
5´-alcohols with a TIPDS ether group was followed by 2´-dimethoxybenzoyl protection 
to ensure β-selectivity during glycosylation. Oxidation of sulfide 177 with mCPBA 
resulted in formation of sulfoxide 178 as a mixture of diastereomers.  
 
Glycosylation of 178 was achieved using the Pummerer method with persilylated uracil 
to give β-uridine analogue 180, as well as thiophene 179. The yield of 180, as well as 
production of 179, was dependent on reaction conditions. The best results were achieved 
when only R-178 was employed in the reaction, resulting in an 87% yield of 180 and no 
by-product formation.  Treatment of 180 with ammonium fluoride, followed by addition 
27 
 
of methanolic ammonia, resulted in deprotection of the 2´-alcohol to form 181 in 85% 
yield. In order to incorporate a 2´-fluorine, 181 was first treated with triflic anhydride in 
the presence of DMAP to form imine 182 via loss of the 2´-hydroxyl. Removal of the 
silyl protecting group in ammonium fluoride afforded 183, which was then fluorinated 
at the 2´-position upon addition of hydrogen fluoride pyridine, producing 2’-deoxy-2´-
fluoro-4´-thiouridine (184) in 87% yield. 
 
To prepare the cytidine analogue, the 5´-hydroxyl of 184 was first protected with a 
dimethoxytrityl group, and the 3´-hydroxyl was subsequently acetylated. Subsequent 
treatment with triphenylsilyl chloride and addition of ammonium hydroxide  facilitated 
the introduction of the 6-amine and simultaneous deprotection of the 3´-hydroxyl group. 
The 3´-hydroxyl was next silylated to allow for selective benzoylation of the 6-amine. 
Removal of the 3´-silyl group was achieved in the usual manner with TBAF to form 
benzoylamine 185. Finally, global deprotection of 185 with TFA afforded cytidine 








Synthesis of the adenine analogue proved more challenging. The adenine derivative of 
180 could not be prepared in sufficient quantities to continue with this route. Thus, an 
alternate approach was taken involving the Vorbrüggen method (Scheme 18).  Inversion 
of the 2´-hydroxyl group of 187 was achieved by way of a Mitsunobu reaction which 
was followed by a swap of the silyl protecting group to an acetal prior to fluorination. 
Alcohol 189 was then treated with perfluoro-1-butanesulfonyl fluoride (PBSF) in the 
presence of DBU to afford 2´-α-fluorinated 190 in 88% yield. To prepare glycosyl bond 
donor 193, the 5´-hydroxyl was protected with a tert-butyldiphenylsilyl group, and 
likewise the 3´-hydroxyl as a para-methoxybenzoyl ester, in order to provide efficient 
neighbouring group participation. Sulfide 191 was oxidised to sulfoxide 192 with ozone. 
Acetylation of 192 afforded 192 which was subjected to Vorbrüggen conditions with 
silylated 6-chloropurine. N
9
-Anomer 194 was initially generated in only 9% yield, with 
the N7-anomer seemingly favoured in this reaction. Heating the mixture of N9- and N7-
isomers resulted in the partial isomerisation of the N
7
-isomer to the desired N
9
-isomer 
after 16 hours. Once separated, the N
7
-isomer was resubjected to the Vorbrüggen 
reaction conditions to afford the N
9
-isomer 194 in 40% yield. The combination of these 
efforts resulted in an overall 52% yield of 194 from 193. Heating of 194 in ammonia 
solution in ethanol effected the conversion of the 6-chloropurine to the adenosine 
analogue, and subsequent removal of the para-methoxybenzoyl group furnished 195 in 
88% yield. Benzoylation of the 6-amino group enabled separation of the α- and β-
anomers by flash chromatography. Finally, the β-isomer was deprotected with TBAF to 






In 2009, a follow-up study by Matsuda et al. outlined the synthesis of very similar 
compounds, with a 2´-methoxy replacing the 2´-fluoro substituent.
45
 The targets were 
synthesised in the same manner as described in Scheme 3, with the methoxy group 
31 
 
arising from the in situ generation of an active nucleophile by the reaction of trimethyl 




Scheme 19  
 
For the purine derivatives, direct methylation of the 2´-hydroxyl group was instead 
employed (Scheme 20).  Methylation of 200 afforded 2´-methoxy analogue 201. 
Selective protection of the 2-amino group with iso-butyryl chloride was carried out prior 
to hydrolysis via diazotization of the 6-amino moiety. Addition of triethylamine 
trihydrofluoride resulted in cleavage of the silyl ether groups, furnishing 202 in 61% 
yield. 
 
The authors did not report any biological activity data for these compounds, but instead 





Scheme 20  
 
3. PUMMERER GLYCOSYLATIONS  
 
Since O’Neil’s novel application of the Pummerer reaction was first published, this 
approach has become increasingly popular, and is extensively employed by chemists in 
the synthesis of thionucleosides.
47
 It involves the use of trimethylsilyltriflate as a 
catalyst to both form the sulfenium ion and to persilylate the nucleobase (Scheme 21). 
 
Scheme 21  
The use of 4´-thioadenosine analogues as human A3 Adenosine Receptor (A3 AR) 
agonists and antagonists has been a major focus in the research literature. Many  of these 
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analogues have been found to be highly potent, selective agonists and a 2004 review on 
thionucleosides includes detailed information on the synthetic routes to such 
compounds.9 Since then, several papers have been published detailing work in this 
area.
48-50
 In each case, D-gulonic-γ-lactone (202) was the starting point in the 
preparation of one of two glycosyl donors 203 or 204 (Scheme 22).51 While conversion 
of sulfoxide 203 to acetate 204 in acetic anhydride allows for glycosylation to proceed 
with marginally better β-selectivity than the direct glycosylation of sulfoxide 203, the 
overall yield of chloropuridine 205 via Route B is lower than Route A (37% vs 54%).38 
Amination of 2,6-dichloropuridine 205 at the 6-position produced 206-208 in high 
yields. The acetal protecting group at the 2´- and 3´-positions was replaced with a bis-
silyl ether before deprotection of the primary alcohol to furnish 209-211. Alcohols 209-
211 were finally transformed over a sequence of steps into the corresponding 







The 4´-thioadenosine analogues all displayed higher binding affinity to the human A3 
AR than the known agonist Cl-IB-MECA (215) (Ki = 1.0 ± 0.2 nM) (Table 8).
52
 The 
highest binding affinity was recorded for 2-chloro-N
6
-methyladenosine-5´-
methyluronamide (214) with Ki = 0.28 ± 0.09 nM. Uronamide analogue 214 was found 
to be selective for the human A3 AR 4800 and 36000 fold more than the A1 and A2A 











1 212 H 0.40 ± 0.06 





3-iodobenzyl 0.38 ± 0.07 
1.0 ± 0.2 
 
A similar synthetic strategy was employed in a study of structure-activity relationships 
of novel 2-chloro-N
6
-substituted-4´-thioadenosine-5´-uronamides as A3 AR agonists.
38
 
To ensure high-affinity binding at the receptor, it was postulated that the presence of a 
hydrogen on the 5´-uronamide moiety is necessary for H-bonding within the binding 
site. It was observed that bulky amines at this position reduced binding affinity. 
Thionucleosides 217 and 235 were both found to exhibit higher binding affinities to the 
A3 AR than their corresponding 4´-oxonucleoside analogues (Table 9, Entries 2 and 20). 
 
 










 Ki (nM) 
1 216 NHCH3 H 0.4 ± 0.06 
2 217 NHCH3 Me 0.28 ± 0.09 
3 218 N(CH3)2 Me 1500 ± 1300 
4 219 Cyclopropyl-NH Me 2.82 ± 1.03 
5 220 Cyclopropylmethyl-NH Me 1.10 ± 0.03 
6 221 Isoamyl-NH Me 1.63 ± 0.17 
7 222 Morpholine Me 3870 ± 580 
8 223 4-Benzyl-piperidine Me 3500 ± 340 
9 224 4-(4-F-Phenyl)-piperazine Me 2700 ± 880 
10 225 3-F-Benzyl-NH Me 17.4 ± 3.8 
11 226 2-(3-F-Phenyl)ethyl-NH Me 85.6 ± 35.6 
12 227 3,3-Diphenyl-propyl-NH Me 415 ± 16 
13 228 NHCH3 Cyclopropyl 2.24 ± 1.21 
14 229 NHCH2CH3 Cyclopropyl 0.67 ± 0.07 
15 230 Cyclopropyl-NH Cyclopropyl 5.56 ± 1.77 
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16 231 4-Benzylpiperidine Cyclopropyl 4020 ± 740 
17 232 Morpholine Cyclopropyl 4440 ± 160 
18 233 NHCH3 Cyclopentyl 4.27 ± 0.33 
19 234 NHCH2CH3 Cyclopentyl 2.83 ± 0.63 
20 235 NHCH3 3-Iodobenzyl 0.38 ± 0.07 
21 236 NHCH2CH3 3-Iodobenzyl 0.89 ± 0.18 
22 237 Iosoamyl-NH 3-Iodobenzyl 41.9 ± 11.3 
23 238 Cyclopropyl-NH 3-Iodobenzyl 2.96 ± 1.03 
24 239 Cyclopropylmethyl-NH 3-Iodobenzyl 3.64 ± 0.60 
25 240 Cyclobutyl-NH 3-Iodobenzyl 18.2 ± 13.4 
26 241 4-Benzylpiperidine 3-Iodobenzyl 878 ± 285 
27 242 4-(4-F-Phenyl)-piperazine 3-Iodobenzyl 1440 ± 830 
28 243 Morpholine 3-Iodobenzyl 510 ± 69 
29 244 3-Cl-Benzyl-NH 3-Iodobenzyl 308 ± 148 
30 245 3-(Trifloromethyl)benzyl-
NH 
3-Iodobenzyl 354 ± 18 
31 246 2-Phenylethyl-NH 3-Iodobenzyl 433 ± 141 
32 247 3,3-Diphenylpropyl-NH 3-Iodobenzyl 343 ± 48 
33 248 NHCH3 2-Methylbenzyl 2.18 ± 0.46 
34 249 NHCH2CH3 2-Methylbenzyl 2.50 ± 1.10 
35 250 N(CH3)2 2-Methylbenzyl 632 ± 70 
36 251 Cyclopropyl-NH 2-Methylbenzyl 27.8 ± 3.80 
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37 252 Cyclopropylmethyl-NH 2-Methylbenzyl 29.7 ± 11.3 
38 253 Morpholine 2-Methylbenzyl 7670 ± 800 
39 254 4-Benzylpiperidine 2-Methylbenzyl 49200 ± 17500 
 
The same authors also investigated the structure-activity relationships of N
6
-substituted-
4´-thioadenosines as agonists at the human A3 AR (Table 10).
38 The most effective and 
suitable agonist tested was the chlorinated analogue 278 (Entry 24), with a Ki value 
comparable to that of Cl-IB-MECA (215). However, this series of compounds was not 
as potent as the corresponding N6-substituted-adenosines or N6-substituted-
4´thioadenosine-5´uronamides listed in Table 9.  
 
Table 10: Binding affinities of thionucleosides 255-290 for the hA3 AR 
 
 
Entry Thionucleoside R KI (nM) or % displ. at 10 
µM 
1 255 NH2 445 ± 54 
2 256 NHCH3 10.3 ± 0.7 
3 257 Cyclopropyl-NH 45.2 ± 5.8 
4 258 Cyclobutyl-NH 48.0 ± 4.9 
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5 259 3-Methyl-butyl-NH 65.3 ± 3.6 
6 260 Cyclopropyl-methyl-NH 22.9 ± 0.8 
7 261 Benzyl-NH 155 ± 33 
8 262 3-Iodo-benzyl-NH 1.9 ± 0.4 
9 263 3-Chloro-benzyl-NH 6.7 ± 0.4 
10 264 3-Methyl-benzyl-NH 13.9 ± 5.7 
11 265 3-Fluoro-benzyl-NH 57.6 ± 12.9 
12 266 3-(Triflouromethyl)-benzyl-
NH 
32.7 ± 6.7 
13 267 Naphth-1-yl-methyl-NH 42.2 ± 13.0 
14 268 2-Phenethyl-NH 5.6 ± 1.1 
15 269 3-Flouro-phenethyl-NH 11.3 ± 0.6 
16 270 trans-2-Phenyl-cyclopropyl-
NH 
6.6 ± 2.9 
17 271 1,2-Diphenyl-ethyl-NH 1080 ± 70 
18 272 3,3-Diphenyl-propyl-NH 1650 ± 150 
19 273 Piperidine 21% 




22 276 Morpholine 16% 
23 277 NH2 4.9 ± 1.3 
24 278 NHCH3 0.8 ± 0.1 
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25 279 Cyclopentyl-NH 94.4 ± 29.2 
26 280 Benzyl-NH 18.2 ± 2.6 
27 281 2-Methyl-benzyl-NH 18.9 ± 16.6 
28 282 2-Ethyloxy-benzyl-NH 17.2 ± 2.2 
29 283 3-Iodo-benzyl-NH 3.2 ± 0.9 
30 284 α-Naphthylmethyl-NH 268 ± 185 
31 285 Fluoren-9-yl-methyl-NH 50.4 ± 26.5 
32 286 2-Phenethyl-NH 4.40 ± 0.33 
33 287 3-Fluoro-phenethyl-NH 4.7 ± 1.6 
34 288 1,2-Diphenylethyl 1300 ± 610 
35 289 trans-2-Phenyl-cyclopropyl-
NH 
1.9 ± 0.4 
36 290 3,3-Diphenyl-propyl-NH 720 ± 193 
 
In 2009, Jeong and co-workers again focused on the 5´-uronamides as potential A3 AR 
agonists.49 They discovered that while bulky amine substituents are tolerated, smaller 
alkyl substituents are preferable. 5´-Methyluronamide 301 was revealed as the most 
effective agonist of those tested (Table 11, Entry 11). Several compounds tested were 
more potent than the known A3 AR agonist IB-MECA (291). 
 












1 291 Me 4-Iodobenzyl H 1.0 
2 292 Me Me Cl 0.28 ± 0.09 
3 293 Me 4-Iodobenzyl  Cl 0.38 ± 0.07 
4 294 Me Me H 1.19 ± 0.23 
5 295 Et Me H 0.97 ± 0.23 
6 296 Cyclopropyl Me H 2.16 ± 0.24 
7 297 Cyclopropylmethyl Me H 1.35 ± 0.08 
8 298 Cyclobutyl Me H 1.04 ± 0.05 
9 299 Cyclopentyl Me H 0.97 ± 0.007 
10 300 3-Iodobenzyl Me H 15.6 ± 5.6 
11 301 Me 4-Iodobenzyl H 0.25 ± 0.06 
12 302 Et 4-Iodobenzyl H 0.42 ± 0.22 
13 303 Cyclopropyl 4-Iodobenzyl H 3.03 ± 0.23 
14 304 Cyclopropylmethyl 4-Iodobenzyl H 2.16 ± 0.29 
15 305 Cyclobutyl 4-Iodobenzyl H 1.17 ± 0.16 
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16 306 Cyclohexyl 4-Iodobenzyl H 35.4 ± 10.5 
17 307 3-Fluorobenzyl 4-Iodobenzyl H 61.1 ± 17.6 
18 308 3-Chlorobenzyl 4-Iodobenzyl H 144 ± 33 
19 309 2-Methylbenzyl 4-Iodobenzyl H 31.0 ± 7.1 
20 310 3-Methylbenzyl 4-Iodobenzyl H 94.9 ± 37.3 
21 311 4-Methylbenzyl 4-Iodobenzyl H 135 ± 55 
22 312 2-Methoxylbenzyl 4-Iodobenzyl H 97.0 ± 51.2 
23 313 2-Ethoxybenzyl 4-Iodobenzyl H 113 ± 2 
24 314 α-Naphthylmethyl 4-Iodobenzyl H 1200 
25 315 2-Phenylethyl 4-Iodobenzyl H 433 ± 141 
26 316 1,1-Diphenylethyl 4-Iodobenzyl H 116 ± 48 
 
The structure-activity relationship of a series of 2-chloro-N
6
-substituted-4´-
thioadenosine-5´-N,N-dialkylamides as A3 Adenosine Receptor (A3 AR) antagonists was 
outlined by Jeong and co-workers.
50
  This class of compound was identified after 
molecular modelling of the A3 AR indicated the N,N-dialkyl substituent destroys the 
hydrogen bond-donating ability of the 5´-uronamide, which is a prerequisite for the 
conformational change needed for receptor activation. Removal of the H-bond donors 
results in the complete loss of A3 AR activation ability, allowing the N,N-dialkyl series 
to act as pure antagonists. The study demonstrated that steric factors of the 5´-position 
play an important role in the binding affinity – in general, the dimethyl derivatives were 
more active than the bulkier analogues (Table 12). 










Ki (nM ± 
SEM) 
1 317 3-Iodobenzyl Me Me 15.5 ± 3.1 
2 318 3-Fluorobenzyl Me Me 121 ± 11 
3 319 3-Chlorobenzyl Me Me 21.3 ± 2.1 
4 320 3-Bromobenzyl Me Me 9.32 ± 3.2 
5 321 N6 (CH3)2 Me Me 136 
6 322 2-Methoxyethyl Me Me 425 
7 323 Cyclopropyl Me Me 109 ± 16 
8 324 Cyclopropylmethyl Me Me 30.7 ± 9.4 
9 325 Cyclobutyl Me Me 115 ± 50 
10 326 Cyclopentyl Me Me 837 
11 327 3-Iodobenzyl Me Propyl 727 
12 328 3-Iodobenzyl Me CH2CH2OH 126 ± 17 
13 329 3-Iodobenzyl Et Phenyl 398 
14 330 3-Iodobenzyl Piperidine - 565 





16 332 3-Iodobenzyl Azetidine - 43.4 ± 2.6 
17 333 3-Iodobenzyl Pyrrolidine - 117 ± 31 
18 334 3-Iodobenzyl 4-
Hydroxypiperidine 
- 1530 
19 335 3-Iodobenzyl Thiomorpholine - 867 
 
A 1,3-dipolar cycloaddition of thiocarbonyl ylides with alkenes bearing electron 
withdrawing substituents was exploited by Corsaro and colleagues in an effort to 
increase yields over previously published methods (Scheme 23).
53
 Cleavage of the 
trimethylsilyl moiety of 337 with cesium fluoride afforded a thiocarbonyl ylide, which 
underwent an in situ 1,3-diopolar cycloaddition with methyl maleate (336) to produce 
tetrahydrothiophene 338. Reduction of diester 338 to diol 339 was achieved with lithium 
aluminium hydride in 66% yield. Protection of 339 with benzoyl chloride furnished 340 
which was oxidised to sulfoxide 341. Glycosylations were achieved using a Pummerer-
type reaction with a suitable silylated nucleobase, trimethylsilyl triflate and triethyl 
amine. The authors report that the α-anomers formed more readily, which they attributed 
to the presence of the bulky benzoyl groups. When the trans-isomer of fumarate 336 
was used as the starting olefin, β-anomer (R,S,R)-342 predominated. Deprotection of the 





Scheme 23  
A library of 4´-thionucleosides was prepared using several different glycosylation 
methods: the Pummerer-type seen in Scheme 23 (compound 343), as well as 
Electrophilic (compound 344) and Vorbrüggen-type (compound 345) glycosylations.37, 
38, 48-51, 54-57
 From the yields listed in Table 13, it is clear that the thiocarbonyl ylide 
cycloaddition strategy is a higher yielding and more convenient route to stereospecific 
4´-thionucleosides. Investigations into the antiviral and antitumour activity of the 










Table 13: Yields of thionucleosides 343-345 
 
 
Entry Nucleoside Thymine  Cytosine Uracil 5-F-Uracil Adenine 
1 (S,S,R)-343 75% 69% 79% 76% n/a 
2 (R,S,R)-343 4% 4% 3% 4% n/a 
3 (R,S,S)-343 73.5% 67.5% 76% 74% 62.5% 
4 (S,S,S)-343 4% 4% 3% 4% 5% 
5 (R,S)-344 47% 36% 52% 45% n/a 
6 (S,S)-344 4% 5% 5% 4% n/a 
7 345 46% 45% 38% 40% n/a 
 
Recently, Jeong and colleagues prepared C8-substituted-4´-thionucleosides as potential 
HSP90 (heat shock protein) inhibitors and investigated their anticancer properties.
40
 
Their analogues consisted of two main classes; 5´-substituted-4´-thionucleosides 
synthesised via the Pummerer rearrangement, and 4´-thionucleosides lacking a 5´-
moiety via the Vorbrüggen method described previously (Scheme 12).
37
 Shown here is 
the synthetic pathway to compounds 129 and 138, which displayed the most promising 
biological effects when tested (Scheme 24). 
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L-Lysonolactone derivative 347 was prepared from D-ribose (346) using Batra’s 
previously published procedure
58
, and then converted to benzoate ester 348. Reduction 
of the lactone afforded diol 349 in 90% yield. Conversion of 349 to the mesylate was 
followed by cyclisation to thiolane 350. Acetyl hydrolysis and subsequent silylation 
furnished bis-silyl ether 351. Oxidation of 351 produced sulfoxide 352, which acted as a 
glycosyl donor in an optimised Pummerer-type condensation with modified purine 127 
to form 4´-thionucleoside 353 in 50% yield as the β-anomer, with only trace amounts of 
the α-product reported. Subsequent deprotections afforded alcohol 129 and benzoate 





Koumbis et al. synthesised a range of apiothionucleosides as potential anti-cancer agents 
(Scheme 25).
59
 Lactol 355 was prepared from a mixture of L- and D-arabinose over two 
steps using a known methodology.60-62 Monotosylation of 355 gave tosylate 356 which 
was reduced with lithium aluminium hydride to diol 357. Conversion of 357 to bis-
mesylate 358 was followed by sulfide substitution and subsequent cyclisation to thiolane 
359 in good yields. Oxidation to sulfoxides (S,S,R)-360 and (S,R,R)-360 afforded both 
49 
 
diastereomers in a 10:1 ratio respectively. The authors established that Pummerer 
transformation proceeded with preferential β-addition. The major isomer is the C-2 
substituted β-isomer (R,R,S)-361, as the C-5 position is more hindered on approach. 
Thymine, uracil and acetyl-cytosine analogues 361-363 were successfully prepared. 
Deprotection of the thymine and uracil derivatives was achieved cleanly using 
Amberlyst-15. The same reaction did not proceed in the case of the cytidine derivative, 




Table 14: Yields for thionucleosides 361-366 
Entry Thionucleoside Base Yield 
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1 (S,S,R)-361 Thymine 12% 
2 (S,S,R)-362 Cytosine 14% 
3 (S,S,R)-363 Uracil 14% 
4 (R,R,S)-361 Thymine 60% 
5 (R,R,S)-362 Cytosine 56% 
6 (R,R,S)-363 Uracil 56% 
7 364 Thymine 75% 
8 365 Cytosine 95% 
9 366 Uracil 73% 
 
Biological evaluation of these novel apiothionucleosides indicated that some had 
specific cytotoxic effects on certain cancer cell lines, but none had an inhibitory effect 
on the normal cell line MRC-5 (Table 15). The D-analogues were found to be more 
active in general. 
 
Table 15: Biological evaluation of thionucleosides 364-366 on several cancer cell lines 
   IC50 (μM) 




1 D-364 41 >100 >100 3  5 >100 
2 L-364  30 >100 >100 52  >100 >100 
3 D-365  9 17 >100 10  >100 >100 
4 L-365 >100 12 13 11  >100 >100 
5 D-366  >100 >100 >100 19  8 >100 
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6 L-366 30 >100 >100 14  >100 >100 
 
The same group later reported the synthesis of a slightly modified version of their 
apiothionucleosides whereby the substituent on the 3´-position is a CH2OH moiety.
63
 
The route to these nucleosides was similar to an earlier approach (Scheme 26). 
Reduction of monosilylated lactol 367 with sodium borohydride afforded diol 368, 
which was converted to the corresponding bis-mesylate 369. Target nucleosides were 





These trihydroxylated apiothionucleosides displayed broader cytotoxic activity than 
their dihydroxylated predecessors.  The L-derivatives appear to be more active, a 
reversal of the previous findings (Table 16).  The most active candidate was L-cytidine-
apiothionucleoside L-372 (Entry 6).  
 





Entry Thionucleoside Base  IC50 (μM) 





1 D-370 D-Thymine  24.0 91.8 >100 45.7  21.3 >100 
2 L-370 L-Thymine  21.1 30.9 >100 39.5  16.3 >100 
3 D-371 D-Uracil  32.7 59.3 >100 >100  28.2 86.6 
4 L-371 L-Uracil 22.4 12.9 48.5 71.1  19.4 >100 
5 D-372 D-Cytidine  18.7 56.12 >100 22.0  17.2 >100 
6 L-372 L-Cytidine  29.7 5.4 >100 3.2  18.6 >100 
 
Inspired by the oxetane-containing antibiotic Oxetanocin A
64
, Nishizono et al. designed 
a series of thietane nucleoside analogues (Scheme 27).
65
 Initial benzylation of 373, 
followed by osmium-mediated dihydroxylation, afforded 374. Oxidative cleavage of the 
diol gave aldehyde 375, which was coupled to allylmagnesium chloride (376) to form 
alkene 377. Epoxidation of 377 furnished 378 which was selectively benzylated at the 
primary alcohol and then mesylated at the remaining secondary alcohol to afford 
intermediate 379. Addition of sodium sulfide to 379 furnished thietane 380 in good yield 
as a racemic mixture. Oxidation of 380 was achieved with sodium periodate to produce 
diastereomeric sulfoxides (s,S,R)-381, (r,S,R)-381 and (r,S,S)-381  which were 
subsequently separated. The outcome of the Pummerer reaction was found to be 
dependent on the stereochemistry of the sulfoxide, with sulfoxide (r,S,S)-381 proving 
marginally better. Coupling of (r,S,S)-381  with thymine resulted in a 1:1 mixture of 
protected thietane nucleosides (S,S)-383 and (R,S)-383. Decoupled alkene 382 was also 
53 
 
produced in the reaction 36% yield. Finally, titanium-mediated deprotection of the 
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Interestingly, when the benzyl ethers in 380 were replaced with benzoyl moieties, the 
condensation reaction of the resulting ester 385 with thymine in the presence of silylated 
triflate instead afforded the ring-expanded 4´-thionucleoside 386 in 30% yield (Scheme 
28). The authors postulate that the reaction proceeds via the elimination of a benzoyl 
55 
 
group via the formation of a thiirane, facilitated by the sulfur lone pair. Ring-opening 
promoted by the free benzoyl anion results in the formation of the 5-membered ring in 
the product. Disappointingly, biological testing revealed that neither (S,S)-384 nor 
(R,S)-384 exhibited any anti-HSV activity, even at high concentrations. 
 
 
Scheme 28  
A practical route to 4´-thionucleosides from inexpensive L-arabinose (388) has been 
described by Yoshimura and colleagues (Scheme 29).
66
 Acid-mediated intramolecular 
cyclisation of L-arabinose afforded arabinoside 389, which was subjected to 
regioselective tosylation, and finally, acetylation in acetic anhydride to furnish 390. 
Nucleophilic substitution of the 5´-tosyl group of 390 with potassium thioacetate gave 
391 in 56% yield over 4-steps. Acetal 391 was converted to thioacetal 392 in 71% yield 
over two steps. Acetylation of the cis-diol 392, and subsequent mesylation effected a 
ring-contraction to ultimately form 394. The reaction proceeds via intramolecular 
nucleophilic attack of sulfur at the 5´-position to form an episulfonium ion, followed by 
ring contraction and generation of an aldehyde which is reduced in situ to alcohol 394. 
Silylation at the 5´-position of 394 was followed by in situ oxidation to give sulfoxide 
395 in 64% yield. Following attempts at optimising the Pummerer-type glycosylation in 
a model reaction, cytidine and uridine analogues 397 and 398 respectively, were 
prepared by reaction of 395 with the appropriate persilylated nucleoside base. Treatment 
with acidic resin promoted hydroxyl deprotection to afford 397 in 56% yield with a 1:5 
α:β ratio, and 398 in 85% yield with a 1:6 α:β ratio. Biological activities are not reported 





Scheme 29  
In 2007, Yoshimura and co-workers redirected their attention to the synthesis of novel, 
ring-expanded 4´-thio-apio-thionucleosides.
67
 Prior to forming (±)-epoxide 399 from 
reaction with meta-chloroperoxybenzoic acid (mCPBA), monosilylation of symmetrical 
diol 373 was carried out using McDougal’s methodology (Scheme 30).68 Ring-opening 
of the epoxide with allyl magnesium chloride in the presence of copper iodide formed 
vinyl diol 401, which was subjected to selective sulfonylation at the primary hydroxyl 
group with bulky 2,4,6-triisopropylbenzenesulfonly chloride (TPSCl) to form 402. 
57 
 
Notably, no bis-sulfonylated product was observed in the reaction mixture. Nucleophilic 
substitution of the leaving group with allyl mercaptan, followed by acetylation resulted 
in the formation of key intermediate 404 in 76% yield. Unsaturated thiane 405 was 
formed via olefin metathesis of 404 using Grubb’s 2nd catalyst in 92% yield. Oxidation 
of 405 to sulfoxide 406 preceeded Pummerer-type glycosylation with a 41% yield of 
cis-407 and 29% yield of trans-407. Global deprotection of trans-407 produced trans-





Scheme 30  
The preparation of compounds 414 and 415 was achieved in a similar manner (Scheme 
31). Following cyclisation of 409, the protected alcohol was desilylated to furnish 410. 
Oxidative cleavage, and sodium borohydride-mediated reduction of the resulting 
aldehyde led to the formation of primary alcohol 411, which was oxidised to sulfoxide 
412. Pummer-type glycosylation was subsequently carried out on 412 as previously 
described, giving cis-413 in 45% yield and trans-413 in 22% yield. Silyl deprotection of 
cis-413 in the usual manner yielded 414, a cytidine analogue, while conversion to the 
59 
 
cis-uridine analogue 415 was achieved over three steps from the same precursor. 




In a later paper, the same authors further explored the synthesis of these 6-membered 
thionucleosides (Scheme 32). 
69
 Employing a previously optimised route, sulfoxide 419 
was initially prepared from allylic epoxide 416.67 Pummer-type glycosylation was 
performed with persilylated uracil on 419 to afford trans- and cis-thionucleosides 421 
and 422 in 27% yield each, as well as 9% of γ-adduct 420. Both the yield and ratio of 
products was found to be dependent on both reaction time and whether sulfoxide 419 
was employed as a mixture of diasteromers or not. It was noted that longer reaction 
times promoted the generation of γ-adduct 420 alone. The authors confirmed that this 
outcome was due to the regeneration of an allylic sulfenium ion of the α-positioned 
nucleosides (S,R)-421 and (R,R)-421. Silyl ether deprotection of the mixture, followed 
by crystallisation, saw (S,R)-422 isolated in 33% yield. Alternatively, N3-benzoylation 
of the mixture allowed for (R,R)-423 to be isolated via column chromatography, which 
60 
 
was then desilylated with TBAF to furnish (R,R)-422. Biological activity of these 
compounds was not reported. 
 
Scheme 32  
In an effort to mimic the oxygen-containing sugar moiety of natural nucleosides, Caputo 
et al. synthesised a range of 1,3-dithiolane nucleosides (Scheme 33).
70
 Dithiolane 427 
was prepared from benzoyloxyethanal71 (425) and ethanethiol (426), in the presence of a 
polystyryl diphenylphosphane-iodine complex, a compound which acts as both a Lewis 
acid and a dehydrating agent
72
. Conversion of 427 to chiral sulfoxides 428 was achieved 
via Di Furia-Modena oxidation.
73
 The trans-isomer was predominant in both cases. 
Coupling of these trans-sulfoxides to nucleoside bases was achieved via Pummerer-type 
61 
 
conditions in good yields. Following deprotection of 428, 429 and 430 were isolated as 
their α- and β-anomers. Biological evaluation of the compounds is not reported in the 
paper. 
 
Scheme 33  
A concise synthesis of 1-(3-C-ethynyl-4-thio-β-D-ribofuraosyl)cytosine (441) was 
developed by Matsuda et al. from D-ribose (346) (Scheme 34).74 Diol 175 was prepared 
using the previously published method and subjected to mesylation to provide 431.46 
Optimisation of the nucleophilic bromination of 431 led to dibromide 433 in 56% yield 
after treatment with ten equivalents of dry lithium bromide in methyl ethyl ketone. 
Addition of sodium sulfide effected double nucleophilic substitution and cyclisation to 
the thiolane, which was debenzylated to afford 176. Overall, this seven step route to 178 
was more efficient than the previous approach, which required eleven steps.
46
 Through a 
series of protection and oxidation steps, sulfoxide 178 was obtained in 64% overall 
62 
 
yield. Pummerer-type glycosylation was conducted on 178 to afford uridine analogue 
434. Incorporation of the 3´-alkyl group required several protections and deprotections 
to first form 437 in 41% overall yield. Oxidation of the 3´-hydroxyl group of 437 to 
ketone 438 was achieved via Swern conditions. Deprotection of 5´-hydroxy group 
facilitated β-faced nucleophilic addition of the alkyl group. Accordingly, hydroxy 
ketone 439 was treated with freshly generated cerium (trimethylsilyl)acetylide to furnish 
440. Exhaustive deprotection of 440 afforded 3´-ethynyl-4´-thiocytidine analogue 441 in 
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Scheme 34  
In a later study, the authors outlined a practical route to 4´-thioRNAs and 4´-thioDNAs: 





Figure 2. Novel RNA- and DNA-derived thionucleosides 
In order to prepare the desired 2´-deoxy derivatives, 436 was first converted to 2,2’-O-
anyhydro derivative 450 (Scheme 35). Crude 450 was next brominated using a 
combination of lithium bromide and boron trifluoride diethyl etherate. Bromide 451 was 
subjected to tin-mediated reduction at room temperature. Gratifyingly, no acyclic side 
products resulting from cleavage of the C-S bond were observed. Standard deprotection 
chemistry furnished nucleoside 445 in 80% yield. This synthetic method provides a 
robust pathway to access the 2´-deoxy derivatives on a gram scale. It was found that 
these 4´-thionucleoside analogues have higher resistance to 3´-exonuclease hydrolysis 
than cell native nucleosides, and that fully modified 4´-thioDNA behaves as an RNA-
like mimic. The gene suppression ability of these derivatives was also examined and 
found to be present in those analogues with a 2´-fluoro moiety, via U1 small nuclear 






























































In related work, Matsuda et al. described the synthesis of 2´-C-methyl-4´-thiocytidine 
(460) (Scheme 36).79 Alcohol 453 was converted to ketone 454 via Parikh-Doering 
oxidation.
80
 Methylation of 454 with methyltitanium trichloride afforded a 3:1 ratio of 
both α- and β-addition products 455 and 456 as an inseparable mixture. 
Dimethoxybenzoylation of 455 and 456  facilitated the isolation of 457 after column 
chromatography in 19% yield. Ozone-mediated oxidation of 457 afforded sulfoxide 458 
which was subjected to Pummerer-type glycosylation with N4-benzoylcytosine to 
provide protected nucleoside 459 in 23% yield. Deprotection in the usual manner 






Scheme 36  
The stereoselectivity of the methylation step depends on the choice of alkylating 
reagent. Use of methyl lithium and trimethyl aluminium led exclusively to α-
methylation in 80% yield, while use of a Grignard reagent afforded the α-product in 
52% yield and β-product in 43%.
81, 82
 By contrast, when 4´-thiocytidine analogue 461 
was exposed to the same conditions, only the undesired α-product 462 was recovered 





Scheme 37  
Neither (R,R,S,R)-460 or its α-epimer (R,S,S,R)-460 were found to possess anti-
leukaemia activity in L1210 cells when tested at a concentration of 100 µg/mL. The 
authors suggest that these results indicate that 4´-thioribocytidine derivatives are less 
susceptible to phosphorylation by cellular uridine-cytidine kinase.  
 
4. ELECTROPHILIC GLYCOSYLATIONS  
 
As β-thionucleosides are superior bioisosteric matches for naturally occurring β-
nucleosides, they tend to display significantly higher biologically activity than their α-
counterparts, thus making face-selectivity an important consideration in their synthesis. 
To combat the reduced selectivity associated with Vörbruggen-type and Pummerer-type 
glycosylations, Haraguchi and co-workers developed an alternative methodology 
involving electrophilic glycosylation of thioglycals whereby β-face-selectivity could be 
targeted.
54
 In this approach, an electrophilic glycal donor 10 is glycosylated with a 
persilylated nucleobase in the presence of N-iodosuccinimide or phenylselenylchloride, 





Scheme 38  
Initially, 2-deoxy-D-ribose (463) was converted to thiofuranose 467 over seven steps as 
per the work of Dyson et al. (Scheme 39).
31
 Selective debenzylation of 464 was 
followed by silylation to furnish 465 in 68% yield. Acetolysis of 465 at the 1´-position 
was achieved with mercury(II) acetate and acetic acid. The resulting thioacetal 466 was 
deacetylated to form thiolactol 467. Treatment of 467 with methanesulfonyl chloride 
and 4-dimethylaminopyridine (DMAP) promoted β-elimination of the in situ generated 
mesylate, furnishing the desired glycal 468 in 80% isolated yield. 
 
Scheme 39  
As the face-selectivity in the glycosylation step can be controlled by varying the silyl 
protecting groups on the 3´- and 5´-hydoxyl moieties83, 84, several electrophilic donors 
were prepared in the same manner as 465. Chemoselective oxidation of the 1´-
thiobenzyl group of 469 and 471 was accomplished in the presence of mCPBA (Scheme 
69 
 
40). While several oxidation products were identified, heating the crude mixture in the 
presence of N,N-diisopropylethylamine afforded glycals 470 and 472 in 59% and 57% 
yields respectively. 
 
Scheme 40  
Installation of a phenylselenyl moiety at the 2´-position allowed for the introduction of 
new functionalities and further transformations at a later stage in the synthesis. 
Simultaneous selenation/glycosylation of 468, 470 and 472 proceeded in a face-selective 
manner on varying the silyl protecting groups at the 3´- and 5´-positions. The face-
selectivity of these electrophilic glycosylations could be controlled with β-approach of 
the electrophile favoured in all instances. The bulkier the silyl group, the higher the 
observed β-selectivity (Table 17). 
 
Table 17: Substituents, yields and α:β selectivities for selenides 473-477 
 




1 468 TBDMS Uracil-1-yl 473β, 473α 88% 4:1 
2 470 -(iPr-
2Si)2O- 
Uracil-1-yl 474β, 474α 87% 18:1 
3 472 -tBu2Si- Uracil-1-yl 475β 88% - 
4 472 -tBu2Si- Thymin-1-yl 476β 62% - 
5 472 -tBu2Si- Cytosine-1-yl 477β 85% - 
 
In a further elaboration of this work, Haraguchi and colleagues prepared more complex 
targets, again via electrophilic substitution.
55, 56
 α-Lithiation of 470 with lithium 
diisopropylamide (LDA) in an argon atmosphere afforded 1´-lithiated 478 which 
underwent in situ methylation with methyl iodide to form 1´-carbosubstituted glycal 479 
(Scheme 41). NIS-initiated electrophilic β-glycosylation of 479 with thymine resulted in 
the exclusive formation of the β-product 480 in 57% yield. Radical reduction of 480 
facilitated the removal of the 2´-iodo group, employing triethyl boron as a radical 
initiator in the presence of tributyl tin hydride and oxygen to afford advanced 
intermediate 481 in excellent yield. Alternatively, reaction of 478 with DMF, followed 
by sodium borohydride reduction, produced alcohol 482, which was converted to acetate 
483 in 78% yield. The primary alcohol in 482 was silylated prior to electrophilic β-
glycosylation to exclusively furnish 485 in 70% yield. Finally, tin-mediated 





This desilylated 1´-carbosubstituted-4´-thionucleosides were assessed for anti-HSV-1 
and anti-HIV-1 activity, using 4´-thiothymidine (487) as a control. The data confirmed 






Table 18: Anti-HSV-1 activity of thionucleosides 488-494 vs 4´-thiothymidine (487) 
 






H 0.008 - 
2 488 Me 4 >34.1 
3 489 CH2OH >100 >100 
4 490 CHO 20 >95.1 
5 492 CH=CHCN >100 >100 
6 493 C(OMe)=NH 100 >100 
7 494 CN 20 >100 
 
The same group later turned their attention to 4´-substituted-4´-thiothymidines.
57
 By 
exploiting the electrophilic glycosylation methodology, they proceeded to synthesise 
4´,5´-unsaturated 498 over a series of nine high-yielding steps (Scheme 42). Silyl 
protection of the 3´-hydroxyl group allowed for selective diacetoxylation of the 
neighbouring alkene. Diacetoxylation of 498 was achieved in 56% yield with a mixture 
of lead(IV) acetate  and sodium carbonate in benzene to afford 499. Using a range of 
substituted trimethylsilanes and tin(IV) chloride, it was possible to displace the 4´-
acetoxy groups to form 500-503 in average to good yields, with predominant formation 
of the D-isomer reported. Deprotection of 500-503 was achieved using TBAF and 






































































































Preparation of the 4´-cyano and 4´-ethynyl derivatives proved more complex. 
Deacetylation of thioacetal 500, followed by silylation and acetolysis in mercury(II) 
acetate furnished 508, (Scheme 43). Reaction of 4´-acetate 508 with 
cyanotrimethylsilane and boron trifluorate afforded an α/β mixture of nitrile 510 (37%) 
and isonitrile by-product 509 (9%). Following separation, deprotection of 510 afforded 
4´-thio-4´-cyano nucleoside 511. Reduction of the same mixture with 
diisobutylaluminium afforded 4´-aldehyde 512. Crude 512 was converted to ethynyl 513 
using the Bestmann-Ohira reagent. Finally, deprotection furnished 4´-ethynyl-4´-







When tested for their antiviral activity, the 4´-substituted-4´-thionucleosides exhibited 
some promising results (Table 19). The most potent analogues against HIV-1 and HIV-2 
were found to be the 4´-azido (505), 4´-cyano (511) and 4´-ethynyl (514) derivatives. 
Compounds 511 and 514 were also found to be active against HIV-1M184V, i.e. wild-
type HIV with a methionine to valine mutation at position-184, a well known HIV 
mutant resistant to a number of NRTIs, including lamivudine (3TC). 
75 
 
Table 19: Antiviral activity of selected thionucleosides against HIV-1 and HIV-2 cell 
lines 
 
   HIV-1 HIV-2 








1 504 SPh >100 >100 >100 >100 
2 505 N3 0.02 40 0.024 >10 
3 506 OMe >4.0 >100 1.2 >100 
4 507 CH2CH=CH2 >100 >100 >100 >100 
5 511 C≡N 0.037 >100 0.023 >10 
6 514 C≡CH 0.31 >100 0.13 >10 
 
Following on from their discovery that 4´-ethynyl-stavudine is a more potent HIV 
inhibitor than the NRTI stavudine (d4T),
85, 86
 Tanaka et al. developed a range of 4´-
substituted-4´-thiostavudine analogues.
87
 Heterocycle 515 was prepared according to 
chemistry pioneered by Woodward et al.88 Acid-catalysed aldol addition of 
formaladehyde to 515 was followed by silyl-protection of the resulting alcohol affording 
517 in 85% overall yield. Ketone 517  was converted to enone 518 via treatment with N-
chlorosuccinimide (Scheme 44). Luche reduction of the α,β-unsaturated ketone afforded 
519 and its epimer in 89% yield (ratio ~10:1).89, 90 Acylation of 519 in the conventional 
manner produced esters 520-523 in excellent yields. Following several failed attempts at 
palladium-catalysed allylic substitution of thiofuranoid 520 with a thymine base, 
76 
 
electrophilic glycosylation was finally achieved using N-iodosuccinimide and 
persilylated thymine in acetonitrile.
54, 56, 91, 92
 Selectivity was highest for benzoate 526 
with a 1:10 ratio of α:β isomers and an overall yield of 98%. Pivalate 525 was formed in 
an 88% yield in a 1:1 α:β ratio. 
 
Scheme 44 
Iodide (R,S,R,R)-526 readily underwent 2´-3´-elimination in the presence of activated 
zinc (Scheme 45). This was followed by reduction of the 4´-ester and subsequent Swern 
oxidation to afford aldehyde 527 in 94% yield. Conversion of 527 to alkyne 529 was 
achieved using the Bestmann-Ohira reagent, and finally fluoride-mediated deprotection 





In total, six different 4´-substituted-4´-thionucleosides were analysed for anti-HIV 
activity (Table 20). Alkyne 530 and nitrile 535 were found to display HIV-1 inhibitory 
activity (Entries 2 and 8), suggesting that an sp-hybridised 4´-carbon substituent is an 
important contributory factor to activity. All compounds assayed were found to be non-
cytotoxic in MT-4 cells. Optical resolution of 4´-ethynyl 530 revealed the levo-
enantiomer to be the active isomer, with an EC50 value comparable to that of stavudine 





Table 20: Anti-HIV activity of thionucleosides 530-535 
 
Entry Thionucleoside R MT-4 cell line 
   EC50 (µM) CC50 (µM) 
78 
 
1 530 C≡CH 0.74 >100 
2 levo-530 C≡CH 0.37 >100 
3 dextro-530 C≡CH >20 >100 
4 531 CH2OH >100 >100 
5 532 CO2Me >100 >100 
6 533 CONH2 >100 >100 
7 534 CH=CH2 >100 >100 
8 535 CN 7.6 >100 
9 d4T H 0.51 >100 
10 4´-ethynyl-d4T C≡CH 0.060 >100 
 
 
5. LATE-STAGE CONSTRUCTION OF THE NUCLEOSIDE BASE  
 
In their search for new 3TC analogues where the 1-oxygen is substituted with a 
difluoromethylene group, Wu et al. investigated novel 6´-difluoro-3´-thiopyrimidines 
for possible anti-HIV and anti-HBV activity.94, 95 Their novel approach to accessing 
these targets involved a late-stage construction of the nucleoside base around the amine 
at the glycal position (Scheme 46). 
 
Scheme 46 
The reaction of 3-bromo-3,3-difluoropropene (537) and indium in DMF generated a 
gem-difluoroallylindium which was coupled in situ to aldehyde 536 to form a gem-
79 
 
difluorohomoallyl alcohol, and then triflated and converted to azide 538 in 50% yield 
(Scheme 47).  A Staudinger-type reduction afforded the syn-isomer, which was boc-
protected to afford amine 539 in 90% yield. Osmium tetroxide-catalysed 
dihydroxylation of 539 produced a 1:1 mixture of isomeric products (S,R)-540 and 
(S,S)-540 which were separable by column chromatography. Following selective 
benzoylation of the primary hydroxyl in (S,S)-540, acetal hydrolysis followed by 
oxidative cleavage of the resulting diol revealed an aldehyde which underwent 
spontaneous cyclisation to 542. Reduction of lactol 542 to diol 543 and subsequent 
mesylation at the 1- and 4-positions was followed by sulfide substitution with 
concomitant ring closure, affording thiofuranose 544 as a single stereoisomer. 
Deprotection with trifluoroacetic acid (TFA) produced key amine intermediate 545 in 
85% yield, upon which the scaffold of the pyrimidine base could be built according to 
the procedure of Shaw and Warrener.96 Condensation of 3-ethoxy-2-propenoyl 
isocyanate 546 with the free amine in 545 gave 547 which underwent acid-catalysed 
ring closure to afford protected nucleoside 548. Hydroxyl deprotection was achieved via 
ammonolysis to furnish target uridine analogue 549 in 55% yield from 545. 549 was 













































































































(ii) TPSCl, DMAP, NEt3
(iii) conc. NH3.H2O









6. LATE-STAGE CONSTRUCTION OF THE THIOLANE RING   
 
Chapdelaine et al. described a novel strategy to access both D- and L-series of 4´-oxo- 
and 4´-thionucleosides where iodine-mediated glycosylation occurs prior to cyclisation 







Exploiting the published procedure by Wirsching et al.,
98
 551 was synthesised in three 
steps from D-xylose (354) (Scheme 49). Mesylation of the 4´-hydroxyl group of 551 
afforded acyclic glycal donor 552. Glycosylation of 552 with persilylated thymine 
produced separable syn and anti isomers (R,R,R,S)-553 and (R,R,R,R)-553 in 94% 
overall yield, with the syn isomer favoured by a ratio of 12:1. Cyclisation of thioaminals 
(R,R,R,S)-553 and (R,R,R,R)-553 was achieved via heating at reflux with sodium iodide 
in the presence of pinacolone or 2,6-lutidine to furnish thionucleosides (S,R,R,S)-554  






This chemistry was applied to a library of isomeric analogues of 554 (Table 21). It was 
reported that all cyclisations were diasterospecific and products were obtained in good 
to excellent yields. This novel strategy for accessing thionucleosides by-passes the 
issues associated with complicated glycosylation steps of nucleosides with glycal 
donors. Biological evaluation of these compounds was not reported. 
 
Table 21: Synthesis of thionucleoside 554. 










































7. CONCLUSION  
 
From this review of the recent literature, it is apparent that thionucleosides remain 
molecules worthy of further investigation. The replacement of oxygen with sulfur 
produces bioisosteric analogues of cell-native oxonucleosides, compounds which are 
noteworthy for their increased biological activity, interesting pharmacological profiles 
or improved metabolic stabilities. Their potential as anti-viral agents will have been 
brought into sharper focus in light of the recent COVID-19 global pandemic.
99-101
 The 
past decade has seen increased use of Pummerer-type glycosylations, in addition to the 
well-established Vörbruggen methodology. The medicinal chemist’s synthetic toolkit 
84 
 
has been further augmented by the development of highly selective electrophilic 
glycosylation chemistry pioneered by Haraguchi. As this review demonstrates, recent 
advances in the preparation of thionucleosides have opened up many high-yielding 
synthetic routes to these valuable targets. Thus, there remains many novel 
thionucleoside-based structures yet to be explored, with their full potential as yet 
unrealised.  
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